Atlas Disease Prevention Complete

1. 01BRCA1 and BRCA2 carriers in Germany may be eligible for the GC-HBOC intensified surveillance program at 17 university centers including Charité Berlin, with annual breast MRI typically starting at age 25 to 30 and covered by GKV.
2. 02Lynch-syndrome carriers receive enhanced colorectal screening earlier than the population baseline, typically with annual colonoscopy starting around age 25.
3. 03A pathogenic finding informs cascade testing for first-degree relatives, coordinated by a human-genetics specialist.
4. 04Surgical prevention options exist for some carriers; these are discussed with a human-genetics specialist and a relevant surgical or oncology team, never decided based on a test alone.
5. 05A negative result does not eliminate cancer risk and does not replace routine screening.

1. 01Carriers are referred for structured cardiology surveillance: echocardiogram and cardiac MRI on a defined cadence, plus Holter monitoring when a rhythm disorder is suspected.
2. 02For specific high-risk channelopathy variants, an electrophysiologist evaluates whether an implantable cardioverter defibrillator (ICD) is indicated.
3. 03Family cascade testing identifies relatives who may also benefit from surveillance.
4. 04Lifestyle and competitive-sport recommendations are individualized per variant by the treating cardiologist.

1. 01Factor V Leiden, prothrombin, protein C and S deficiency, and antithrombin deficiency carriers receive concrete travel and surgical precautions -- compression stockings on long-haul flights, prophylactic anticoagulation around major surgery, hospitalization, and pregnancy.
2. 02Hormonal contraception and hormone-replacement decisions are individualized with your physician.
3. 03Family cascade testing identifies relatives at the same risk.

1. 01HFE-hemochromatosis carriers receive regular ferritin and transferrin-saturation monitoring. If iron overload develops, therapeutic phlebotomy is the standard treatment and prevents irreversible liver cirrhosis, diabetes, and cardiomyopathy.
2. 02Wilson-disease carriers (ATP7B) require specialist hepatology and neurology care. Chelation and zinc therapy prevent progressive liver and neurological damage.
3. 03Both conditions are highly treatable when caught early and progressive when missed.

1. 01Familial hypercholesterolemia (FH) affects roughly one in 250 people and is heavily underdiagnosed.
2. 02Untreated FH carries an approximately 20-fold increased lifetime risk of premature coronary heart disease.
3. 03Statin therapy started in young adulthood normalizes lifetime cardiovascular risk close to the population baseline.
4. 04Family cascade testing typically finds additional affected relatives in the same generation and the prior generation.

Atlas medical/product review pending.

1. 01Several of these conditions (Fabry, Gaucher, MPS-I) have specific enzyme-replacement therapies that work best when started before irreversible organ damage.
2. 02Eye findings are often an early visible sign of an underlying systemic disease and prompt a broader work-up.
3. 03Atlas medical review is pending -- this is not a comprehensive hereditary-ophthalmology panel; the five genes cover systemic storage disease with ocular manifestations, not retinal dystrophies or optic neuropathies.

1. 01Carriers must inform every anesthesiology team before any planned surgery, including elective procedures, dental surgery under general anesthesia, and caesarean section.
2. 02Safe alternative anesthetic agents exist and are routine.
3. 03Without disclosure, exposure to volatile anesthetics or succinylcholine can trigger a life-threatening hyperthermic crisis. With disclosure, surgery is routine and safe.
4. 04Family cascade testing is straightforward and relevant for any relative who may have surgery.

1. 01Warfarin dosing (VKORC1, CYP2C9): the correct starting dose prevents bleeding and clotting complications.
2. 02Clopidogrel response (CYP2C19): identifies poor metabolizers for whom alternative antiplatelet agents work better after a heart event or stent.
3. 03Codeine and tramadol (CYP2D6): identifies ultra-rapid metabolizers at risk of overdose and poor metabolizers for whom the drug does not work.
4. 04Capecitabine and 5-FU chemotherapy (DPYD): identifies patients who require dose reduction to prevent severe toxicity.
5. 05Antidepressant selection (CYP2D6, CYP2C19): informs SSRI and tricyclic-antidepressant choice and dose.

1. 01MODY-HNF1A responds well to oral sulfonylureas and often does not require insulin.
2. 02MODY-GCK is a stable, mild hyperglycemia that requires no treatment in most cases.
3. 03A correct molecular diagnosis avoids unnecessary insulin therapy and informs family screening.
4. 04The diagnosis often changes pregnancy management and reproductive planning.

1. 01Specific enzyme-replacement therapies exist for Pompe, Fabry, and Gaucher and prevent irreversible organ damage when started early.
2. 02Alpha-1 antitrypsin deficiency informs lifestyle decisions (smoking, occupational exposure) and pulmonary surveillance.
3. 03Family cascade testing is critical -- many of these conditions have effective treatments only when started before symptoms develop.

1. 01Annual kidney-function monitoring is established practice -- eGFR, blood pressure, and abdominal ultrasound or MRI on a defined cadence.
2. 02Tolvaptan can slow progression in selected patients and is prescribed by a nephrologist.
3. 03Reproductive planning and family cascade testing are part of the standard follow-up.
4. 04Without intervention, ADPKD typically progresses to end-stage kidney disease by the 50s or 60s; with active management, progression is significantly slowed.

1. 01If a finding is identified, follow-up is established medical practice -- this is the international guideline-grade baseline.
2. 02Cancer findings (BRCA1/2, Lynch, TP53) route to oncology surveillance and may qualify for the GC-HBOC program where applicable.
3. 03Cardiac findings (channelopathies, cardiomyopathies, aortopathies) route to cardiology surveillance and, when indicated, electrophysiology evaluation.
4. 04Metabolic findings (Wilson, Pompe, Fabry, OTC, biotinidase) route to specialist-led therapy planning.
5. 05Cascade testing of first-degree relatives is part of the ACMG framework when an actionable variant is identified.